Quick Links

ZVITAMBO Cluster Randomised Trial Project

Project Information
The study will be a cluster-randomized 2X2 factorial design, community-based trial testing the independent and combined effects of two interventions (a sanitation/hygiene intervention and a nutrition intervention) on infant growth and health. The sanitation/hygiene intervention will include household toilet construction and hygiene messages delivered by village health workers to households and through social marketing to communities. The nutrition intervention will include a nutrient supplement for infants between 6-12 months and nutrition messages delivered by village health workers to families of infants.
Project Date: 
07/01/2010 to 06/30/2015
Type of Project: 
Research Area: 
Health Research
Sub-Research Area: 
Other Sub-Research Area: 
Public Health
Funding Source: 
Department for International Development, UK (DfID)
McGill University Project Leader Information
Project Leader: 

Brian Ward

Profile Picture: 
Primary Position
Faculty of Medicine
Microbiology & Immunology
McGill University Health Centre (MUHC)
Research Interests: 
Vaccine-related activities: I am very interested in basic studies of the correlates of immune protection as well as the immunologic correlates of vaccine-associated adverse events. Using measles as our primary model, we have examined immune responses generated following natural infection and vaccination in children of the developed and the developing world. Adverse events after vaccination are a growing concern and the lab has been involved and continues to be involved in studies of adverse events after vaccines for measles (increased mortality after the high titer formulation, autism and Crohns Disease after MMR), pertussis (local and systemic reactions), anthrax (all events), smallpox (death) and influenza (oculo-respiratory syndrome). We are also very interested in the interactions between virus (measles and HIV are our models) and retinoids both in vitro and in the field (Zimbabwe, Peru). We are developing proteosome-based vaccines (nasal delivery) for several respiratory viruses (measles, RSV, PIV3) as well as Toxoplasma gondii (Tg-AMA1) and Leishmania donovani (A2). Finally, we have an active Vaccine Evaluation Center that recruits subjects to ‘first-in-man’ Phase I and Phase II studies. In 2003, we studied a CpG-based hepatitis B vaccine, a pan-serotype, protein-based Streptocossus pneumoniae vaccine and a trivalent proteosome-based influenza vaccine. Parasitology: The lab includes the National Center for Parasitology (NRCP), an external reference laboratory for health Canada that performs almost all diagnostic testing for parasitic diseases in the country. In the past several years he NRCP has developed novel assays or improved assays for a number of parasitic diseases (Chagas disease, leishmania, cyclosporiasis, strongyloidiasis). We have used standard and modified EIA techniques, PCR and SELDI-ToF MS. We are also actively involved in the development of novel treatments for parasitic diseases including imiquomod for leishmaniasis (Peru) and protease inhibitors for C parvum. (IFNg receptor KO mouse model) and c-MET antagonists for malaria (P berghei model).
Selected Publications: 

Sampasa-Kanyinga H, Lévesque B, Anassour-Laouan-Sidi E, Côté S, Serhir B, Ward BJ, Libman MD, Drebot MA, Ndao M, Dewailly E.
Zoonotic Infections in Native Communities of James Bay, Canada. Vector Borne Zoonotic Dis. 2012 Jan 4. [Epub ahead of print]

Wagar LE, Rosella L, Crowcroft N, Lowcock B, Drohomyrecky PC, Foisy J, Gubbay J, Rebbapragada A, Winter AL, Achonu C, Ward BJ, Watts TH.
Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One. 2011;6(11):e28063. Epub 2011 Nov 23.

Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, Chan T, Petric M.
Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J. 2011 Oct;30(10):833-9.

Soye KJ, Trottier C, Richardson CD, Ward BJ, Miller WH Jr.
RIG-I is required for the inhibition of measles virus by retinoids. PLoS One. 2011;6(7):e22323. Epub 2011 Jul 19.

Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabaiduc S, Petric M. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011 Aug;128(2):e276-89. Epub 2011 Jul 18.

Principal Investigator
Non-McGill Partners
Jean Humphrey